Supporting the goals and ideals of "National Sudden Cardiac Arrest Awareness Month".

Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.

Client expense: $1,079,232 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Client expense: $1,071,595 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues

Client expense: $836,600 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE